Companies › Sinotau Pharmaceutical Group
6 active drug programs in 6 registered trials: 3 Phase 3, 2 Phase 2, 1 Phase 1; Oncology, Cardiovascular, Neurology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| XTR004 PET myocardial perfusion imaging agent | – | Phase 3 | Coronary Artery Disease(CAD) | Jun 2027 |
| Lutetium Oxodotreotide Lu-177 Somatostatin receptor binding agent | SSTR5, SSTR2, SSTR4, SSTR1, SSTR3 | Phase 3 | Neuroendocrine Tumors | Dec 2028 |
| [18F]XTR006 PET radiopharmaceutical selective for neurofibrillary tangles (NFTs) | – | Phase 3 | Alzheimer Disease | – |
| XTR003 Injection PET imaging agent for myocardial fatty-acid metabolic imaging | – | Phase 2 | Ischemic Cardiomyopathy | Dec 2026 |
| Lutetium[177Lu] Oxodotreotide Injection Somatostatin receptor 2 (SSTR2)-targeting peptide receptor radionuclide therapy (PRRT) wit | SSTR2 | Phase 2 | Advanced Neuroendocrine Neoplasm | Jun 2027 |
| Flotufolastat F-18 Injection PSMA-targeted PET imaging tracer | PSMA | Phase 1 | Prostate Cancer | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07115238 | [18F]XTR006 | Phase 3 | Alzheimer Disease | Neurology | Dec 2025 |
| NCT07149831 | Flotufolastat F-18 Injection | Phase 1 | Prostate Cancer | Oncology | Dec 2025 |
| NCT07443696 | XTR003 Injection | Phase 2 | Ischemic Cardiomyopathy | Cardiovascular | Dec 2026 |
| NCT06398444 | Lutetium[177Lu] Oxodotreotide Injection | Phase 2 | Advanced Neuroendocrine Neoplasm | Oncology | Jun 2027 |
| NCT07439133 | XTR004 | Phase 3 | Coronary Artery Disease(CAD) | Cardiovascular | Jun 2027 |
| NCT05459844 | Lutetium Oxodotreotide Lu-177 | Phase 3 | Neuroendocrine Tumors | Oncology | Dec 2028 |
Lantheus Medical Imaging Clarity Pharmaceuticals Norroy Bioscience POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company RayzeBio
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.